Experimental cancer combo shows early promise, but trial halted

NCT ID NCT05147272

Terminated Disease control Sponsor: Debiopharm International SA Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new oral drug (RP-6306) combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety, find the best dose, and see if the combination could shrink tumors. The trial was terminated early, so final results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RP-6306 (a PKMYT1 inhibitor) combined with gemcitabine
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This was a very early (Phase 1) trial that was terminated, so results are limited. The combination may cause significant side effects, and it is unclear if it will work for most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT SOLID TUMOR

Contacts and locations

Locations

# 1004, Memorial Sloan Kettering Cancer Institute

New York, New York, 10065, United States
# 1008, Columbia University

New York, New York, 10032, United States
# 1010, University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
# 1016, Mayo Clinic

Rochester, Minnesota, 55902, United States
# 1017, Mayo Clinic

Jacksonville, Florida, 32224, United States
# 1018, Mayo Clinic

Phoenix, Arizona, 85054, United States
# 1019, UCLA, Westwood Cancer Center

Los Angeles, California, 90095, United States
# 1022, Moffitt Cancer Center

Tampa, Florida, 33612, United States
# 1023, START Midwest

Grand Rapids, Michigan, 49546, United States
# 2001, Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2C1, Canada
# 3003, Sarah Cannon Research Institute

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.